Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 3, 2003, Pages 519-523

  Pae, Chi Un ^a   Kim, Jung Jin ^a,b,e   Lee, Soo Jung ^a   Lee, Chang Uk ^a   Lee, Chul ^a   Paik, In Ho ^a   Park, Ho Ran ^c   Yang, Soo ^c   Serretti, Alessandro ^d  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c The Catholic University of Korea College of Medicine   (South Korea)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e Korea University College of Medicine   (South Korea)

Author keywords

Association study; Glutathione S transferase P gene (GSTP1) polymorphism; Korea; Schizophrenia

Indexed keywords

GLUTATHIONE TRANSFERASE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; GSTP1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATHOGENESIS; POLYMERASE CHAIN REACTION; RATING SCALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA;

EID: 0037402528     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00043-5     Document Type: Article

References (41)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Press, Washington, DC.
2. Arnold S.E., Trojanowski J.Q. Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathol. (Berl.). 92:1996;217-231.
3. Behl C., Moosmann B. Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds. Biol. Chem. 383:2002;521-536.
4. Benkmann H.G., Cho Y.H., Singh S., Wimmer U., Lee C.C., Kim I.K., Paik Y.K., Goedde H.W. Red cell enzyme and serum protein polymorphisms in South Korea. Hum. Hered. 39:1989;263-270.
5. Catts V.S., Catts S.V. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophr. Res. 41:2000;405-415.
6. DeLisi L.E., Tew W., Xie S., Hoff A.L., Sakuma M., Kushner M., Lee G., Shedlack K., Smith A.M., Grimson R. A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings. Biol. Psychiatry. 38:1995;349-360.
7. DeLisi L.E., Sakuma M., Tew W., Kushner M., Hoff A.L., Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 74:1997;129-140.
8. DeLisi L.E., Sakuma M., Ge S., Kushner M. Association of brain structural change with the heterogeneous course of schizophrenia from early childhood through five years subsequent to a first hospitalization. Psychiatry Res. 84:1998;75-88.
9. Duman R.S., Heninger G.R., Nestler E.J. Molecular psychiatry. Adaptations of receptor-coupled signal transduction pathways underlying stress- and drug-induced neural plasticity. J. Nerv. Ment. Dis. 182:1994;692-700.
10. Erdfelder E., Faul F., Buchner A. GPOWER: a general power analysis program. Behav. Res. Meth. Instrum. Comput. 28:1996;1-11.
11. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-Clinician Version (SCID-CV). 1997;American Psychiatric Press, Washington, DC.
12. Gelernter J., Pakstis A.J., Grandy D., Litt M., Retief A.E., Kennedy J.L., Hing-Loh A., Schoolfield G., Civelli O., Kidd K.K. Linkage map of eight human chromosome 11q markers, including DRD2, spanning 60 cM. Cytogenet. Cell Genet. 60:1992;26-28.
13. Gopal P.V., Sriram A.V., Sharma D., Singh R. Glutathione-S-transferase in the ageing rat brain cerebrum and the effect of chlorpromazine. Gerontology. 46:2000;7-11.
14. Harries L.W., Stubbins M.J., Forman D., Howard G.C., Wolf C.R. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 18:1997;641-644.
15. Harrison P.J., Eastwood S.L. Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia. Lancet. 352:1998;1669-1673.
16. Hoyt K.R., Gallagher A.J., Hastings T.G., Reynolds I.J. Characterization of hydrogen peroxide toxicity in cultured rat forebrain neurons. Neurochem. Res. 22:1997;333-340.
17. Hu X., Xia H., Srivastava S.K., Pal A., Awasthi Y.C., Zimniak P., Singh S.V. Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c]phenanthrene and benzo[g]chrysene. Cancer Res. 58:1998;5340-5343.
18. Ishisaki A., Hayashi H., Suzuki S., Ozawa K., Mizukoshi E., Miyakawa K., Suzuki M., Imamura T. Glutathione S-transferase Pi is a dopamine-inducible suppressor of dopamine-induced apoptosis in PC12 cells. J. Neurochem. 77:2001;1362-1371.
19. Jeronimo C., Varzim G., Henrique R., Oliveira J., Bento M.J., Silva C., Lopes C., Sidransky D. I105 V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol. Biomark. Prev. 11:2002;445-450.
20. Kawasak Y., Vogeley K., Jung V., Tepest R., Hutte H., Schleicher A., Falkai P. Automated image analysis of disturbed cytoarchitecture in Brodmann area 10 in schizophrenia: a post-mortem study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 24:2000;1093-1104.
21. Kay S.R., Opler L.A., Lindenmayer J.P. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res. 23:1988;99-110.
22. Kyosseva S.V., Owens S.M., Elbein A.D., Karson C.N. Differential and region-specific activation of mitogen-activated protein kinases following chronic administration of phencyclidine in rat brain. Neuropsychopharmacology. 24:2001;267-277.
23. Margolis R.L., Chuang D.M., Post R.M. Programmed cell death: implications for neuropsychiatric disorders. Biol. Psychiatry. 35:1994;946-956.
24. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated acid. Nucleic Acids Res. 16:1988;1215.
25. Mulcrone J., Whatley S.A., Marchbanks R., Wildenauer D., Altmark D., Daoud H., Gur E., Ebstein R.P., Lerer B. Genetic linkage analysis of schizophrenia using chromosome 11q13-24 markers in Israeli pedigrees. Am. J. Med. Genet. 60:1995;103-108.
26. Nerurkar P.V., Okinaka L., Aoki C., Seifried A., Lum-Jones A., Wilkens L.R., Le Marchand L. CYP1A1, GSTM1, and GSTP1 genetic polymorphisms and urinary 1-hydroxypyrene excretion in non-occupationally exposed individuals. Cancer Epidemiol. Biomark. Prev. 9:2000;1119-1122.
27. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10:1962;799-812.
28. Pritchard J.K., Rosenberg N.A. Use of unlinked genetic markers to detect population stratification in association studies. Am. J. Hum. Genet. 65:1999;220-228.
29. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot. Essent. Fatty Acids. 55:1996;33-43.
30. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 71:1998;1002-1012.
31. Sato K. Glutathione transferases as markers of preneoplasia and neoplasia. Adv. Cancer Res. 52:1989;205-255.
32. Smythies J. On the functional of neuromelanin. Proc. R. Soc. Lond B. Biol. Sci. 263:1996;487-489.
33. Smythies J. Redox mechanisms at the glutamate synapse and their significance: a review. Eur. J. Pharmacol. 370:1999;1-7.
34. Spielman R.S., McGinnis R.E., Ewens W.J. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am. J. Hum. Genet. 52:1993;506-516.
35. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr. Res. 32:1998;1-8.
36. Yao J.K., Reddy R.D., van Kammen D.P. Plasma glutathione peroxidase and symptom severity in schizophrenia. Biol. Psychiatry. 45:1999;1512-1515.
37. Yao J.K., Reddy R., van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res. 97:2000;137-151.
38. 2-induced cell death via coordinated regulation of stress kinases. Cancer Res. 60:2000;4053-4057.
39. Yoshioka M., Tanaka K., Miyazaki I., Fujita N., Higashi Y., Asanuma M., Ogawa N. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci. Res. 43:2002;259-267.
40. Yoshizumi M., Kogame T., Suzaki Y., Fujita Y., Kyaw M., Kirima K., Ishizawa K., Tsuchiya K., Kagami S., Tamaki T. Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells. Br. J. Pharmacol. 136:2002;1023-1032.
41. 2-induced apoptosis in human neuronal cells. Biochem. Biophys. Res. Commun. 235:1997;845-848.